Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8048126 | 0.98 | MAPT (0.55) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL5250642 | 0.85 | LMNA (0.47) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL8204434 | 0.85 | MAPT (0.56) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL3285239 | 0.85 | MAPT (0.56) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL4007518 | 0.85 | MAPT (0.56) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL8402126 | 0.83 | MAPT (0.55) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL14097078 | 0.83 | LMNA (0.68) | MAPTALDH1A1LMNAPOLBKDM4E | |
| Hydrochloric Acid SCHEMBL31066894 | 0.83 | MAPT (0.55) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL3057252 | 0.83 | MAPT (0.55) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL3614239 | 0.82 | KDM4E (0.51) | MAPTALDH1A1LMNAPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| CN-112661772-A | Interferon gene stimulating protein compound and preparation method thereof | 杭州阿诺生物医药科技有限公司 | 2021-04-16 | — | — | CN | claimed |
| CN-112279835-A | Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2021-01-29 | — | — | CN | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| CN-1826121-B | Application of phenyl and pyridyl derivatives in preparation of drugs for regulating calcium ion release and activating calcium ion channels | SYNTA PHARMACEUTICALS CORP | 2013-05-29 | — | — | CN | claimed |
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1653968-A4 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-06 | — | — | EP | claimed |
| CN-1826121-A | Method for regulating and controlling calcium ion release to activate calcium ion channel | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| CN-1826120-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| EP-1653968-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | Synta Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1651232-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | claimed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | claimed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | MAPT 539/4885ALDH1A1 953/4885LMNA 2106/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | MAPT 539/4885ALDH1A1 953/4885LMNA 2106/4885 |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | ORAI1, CACNA1C, CACNA1F | MAPT 1863/4885ALDH1A1 2803/4885LMNA 225/4885 |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, PTPN3, FKBP3 | MAPT 455/4885ALDH1A1 1281/4885LMNA 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.